Lareb Intensive Monitoring: An Interim Analysis

Autor:	E P van Puijenbroek, L. Harmark, A C van Grootheest, Ingrid Oosterhuis
Rok vydání:	2007
Předmět:	Pharmacology business.industry Pharmacy Toxicology Interim analysis medicine.disease chemistry.chemical_compound chemistry Spontaneous reporting Pharmacovigilance medicine Duloxetine Pharmacology (medical) Drug reaction Medical emergency business
Zdroj:	Drug Safety. 30:919-990
ISSN:	0114-5916
DOI:	10.2165/00002018-200730100-00112
Popis:	Background In August 2006, the Netherlands Pharmacovigilance Centre Lareb started with Lareb Intensive Monitoring (LIM). The main objective of LIM is to monitor the safety of new drugs. Patients eligible for participation are identified using the first dispensing signal in the pharmacy. After registration on www.larebmonitor.nl, questionnaires are sent to the patient at specific points in time asking for their experiences with the drug, including Adverse Drug Reactions (ADRs). LIM gives the opportunity to follow drugs more closely than with the current spontaneous reporting system. At the moment, pregabaline and duloxetine are being monitored.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::54ca434d222c7853e057b6394adff432 https://doi.org/10.2165/00002018-200730100-00112 Zobrazit plný text záznamu Full text from SpringerLink